475 related articles for article (PubMed ID: 27770771)
1. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
3. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
4. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
6. Ambrisentan therapy for pulmonary arterial hypertension.
Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
[TBL] [Abstract][Full Text] [Related]
8. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
9. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
Safdar Z
Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
[TBL] [Abstract][Full Text] [Related]
11. [Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients].
He J; Wen L; Jiang R; Zhao QH; Wang L; Jiang X; Yan P; Bai L; Jing ZC
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun; 41(6):493-6. PubMed ID: 24113042
[TBL] [Abstract][Full Text] [Related]
12. [Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension].
Wen L; Jiang X; An P; He J; Zheng L; Liu Q; Peng F; Xu X; Jing Z
Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun; 42(6):469-73. PubMed ID: 25164219
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of ambrisentan therapy in Chinese patients with pulmonary hypertension].
Chen FD; Zhou DX; Di RM; Zou Y; Wei W; Liu XB
Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(34):2736-8. PubMed ID: 24360110
[TBL] [Abstract][Full Text] [Related]
14. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Nakahara N; Iwase T; Nakajima H
Curr Med Res Opin; 2011 Sep; 27(9):1827-34. PubMed ID: 21812736
[TBL] [Abstract][Full Text] [Related]
16. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
[TBL] [Abstract][Full Text] [Related]
17. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
[TBL] [Abstract][Full Text] [Related]
18. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
[TBL] [Abstract][Full Text] [Related]
19. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
20. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
